Literature DB >> 18378206

Strontium ranelate promotes osteoblastic cell replication through at least two different mechanisms.

Joseph Caverzasio1.   

Abstract

The cellular and molecular mechanisms involved in osteoblastic cell replication induced by strontium ranelate are presently under investigation. The calcium-sensing receptor is a suggested target but other potential mechanisms have not been investigated. Signaling pathways involved in strontium ranelate-induced replication were investigated in preosteoblastic MC3T3-E1 and pluripotent mesenchymal C3H10T1/2 cells. Strontium ranelate effects were compared with those of calcium chloride as Ca(2+). In MC3T3-E1 cells, strontium ranelate but not CaCl(2) dose-dependently increased cell number whereas similar effects were observed for both cations in C3H10T1/2 cells. Immunoblot analysis indicated that activation of ERK, PKC and PKD by strontium ranelate in MC3T3-E1 cells was delayed compared with CaCl(2). Indeed, onset of signaling by strontium ranelate was detected after one or several hours whereas CaCl(2) had a maximal effect already after 5 min exposure. In C3H10T1/2 cells, strontium ranelate induced two types of signaling, a rapid effect and a delayed response. In addition to activation of ERK, PKC and PKD, strontium ranelate and CaCl(2) also transiently activated p38 in C3H10T1/2 cells. Functional analysis with specific inhibitors indicated that cell replication induced by strontium ranelate involves a PKC/PKD pathway in MC3T3-E1 cells and p38 in C3H10T1/2 cells. In both cell types, inhibition of the ERK pathway decreased basal cell replication but not the strontium ranelate response. In conclusion, strontium ranelate increases the replication of cells of the osteoblastic lineage by two distinct cellular mechanisms. Strontium ranelate may directly interact with the CaSR and trigger mitogenic signals such as p38 in C3H10T1/2 cells. The delayed activation of several signaling pathways in both cell lines, however, suggests the release of an autocrine growth factor by strontium ranelate that represents another potential mechanism for inducing osteoblastic cell replication.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18378206     DOI: 10.1016/j.bone.2008.02.010

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  44 in total

1.  Substituted hydroxyapatites for bone repair.

Authors:  Jennifer H Shepherd; David V Shepherd; Serena M Best
Journal:  J Mater Sci Mater Med       Date:  2012-03-03       Impact factor: 3.896

2.  Strontium Ranelate: Long-Term Efficacy against Vertebral, Nonvertebral and Hip Fractures in Patients with Postmenopausal Osteoporosis.

Authors:  Jean-Yves Reginster; Mickaël Hiligsmann; Olivier Bruyere
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-06       Impact factor: 5.346

3.  Strontium fructose 1,6-diphosphate prevents bone loss in a rat model of postmenopausal osteoporosis via the OPG/RANKL/RANK pathway.

Authors:  Bo Ma; Qi Zhang; Di Wu; Yong-lu Wang; Ying-ying Hu; Yan-ping Cheng; Zhen-dong Yang; Ya-ya Zheng; Han-Jie Ying
Journal:  Acta Pharmacol Sin       Date:  2012-03-19       Impact factor: 6.150

4.  Aging and bone loss: new insights for the clinician.

Authors:  Oddom Demontiero; Christopher Vidal; Gustavo Duque
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-04       Impact factor: 5.346

5.  Strontium-substituted hydroxyapatite stimulates osteogenesis on poly(propylene fumarate) nanocomposite scaffolds.

Authors:  Jingfeng Li; Xifeng Liu; Sungjo Park; A Lee Miller; Andre Terzic; Lichun Lu
Journal:  J Biomed Mater Res A       Date:  2018-11-25       Impact factor: 4.396

Review 6.  How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis.

Authors:  P J Marie; D Felsenberg; M L Brandi
Journal:  Osteoporos Int       Date:  2010-09-02       Impact factor: 4.507

Review 7.  Strontium ranelate: a review of its use in the treatment of postmenopausal osteoporosis.

Authors:  Emma D Deeks; Sohita Dhillon
Journal:  Drugs       Date:  2010-04-16       Impact factor: 9.546

8.  The effect of strontium incorporation in hydroxyapatite on osteoblasts in vitro.

Authors:  Guo-Xin Ni; Zhi-Peng Yao; Guo-Tao Huang; Wen-Ge Liu; William W Lu
Journal:  J Mater Sci Mater Med       Date:  2011-03-02       Impact factor: 3.896

9.  Systemic treatment with strontium ranelate promotes tibial fracture healing in ovariectomized rats.

Authors:  Y F Li; E Luo; G Feng; S S Zhu; J H Li; J Hu
Journal:  Osteoporos Int       Date:  2009-12-03       Impact factor: 4.507

10.  In vivo study of porous strontium-doped calcium polyphosphate scaffolds for bone substitute applications.

Authors:  Meng Tian; Feng Chen; Wei Song; Yancheng Song; Yuanwei Chen; Changxiu Wan; Xixun Yu; Xiaohua Zhang
Journal:  J Mater Sci Mater Med       Date:  2009-03-09       Impact factor: 3.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.